Andere Sprachen Jazz Pharmaceuticals plc

Aktien

A1JS1K

IE00B4Q5ZN47

JAZZ

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.05.2024			% 5 Tage	% 1. Jan.
111.2 ^USD	+1.24%		+0.42%	-9.59%

07.05.	Jazz Pharmaceuticals Insider verkaufte Aktien im Wert von $548.250, laut einer aktuellen SEC Einreichung	MT
03.05.	JAZZ PHARMACEUTICALS PLC : UBS gibt neutrale Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing	07.05.
Jazz Pharmaceuticals : Corporate Overview	03.05.
Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results	02.05.
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook	02.05.
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35	01.05.
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q1 Revenue $902M, vs. Street Est of $954.3M	01.05.
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q1 EPS $2.68, vs. Street Est of $4.18	01.05.
Jazz: Q1 Earnings Snapshot	01.05.
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference	01.05.
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance	01.05.
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024	01.05.
Jazz Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	01.05.
Jazz Pharmaceuticals to Present Data across Growing Oncology Pipeline and Portfolio at ASCO 2024	25.04.
The PharmaMar Group presents financial results for the first quarter of 2024	24.04.
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024	17.04.
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	02.04.
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	02.04.
Jazz Pharmaceuticals : Zanidatamab R&D Day	19.03.
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024	12.03.
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)	07.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Jazz Pharmaceuticals plc

Aktien

A1JS1K

IE00B4Q5ZN47

JAZZ

Andere Sprachen

Filter